Literature DB >> 32958242

The role of prion strain diversity in the development of successful therapeutic treatments.

Sara A M Holec1, Alyssa J Block2, Jason C Bartz3.   

Abstract

Prions are a self-propagating misfolded conformation of a cellular protein. Prions are found in several eukaryotic organisms with mammalian prion diseases encompassing a wide range of disorders. The first recognized prion disease, the transmissible spongiform encephalopathies (TSEs), affect several species including humans. Alzheimer's disease, synucleinopathies, and tauopathies share a similar mechanism of self-propagation of the prion form of the disease-specific protein reminiscent of the infection process of TSEs. Strain diversity in prion disease is characterized by differences in the phenotype of disease that is hypothesized to be encoded by strain-specific conformations of the prion form of the disease-specific protein. Prion therapeutics that target the prion form of the disease-specific protein can lead to the emergence of drug-resistant strains of prions, consistent with the hypothesis that prion strains exist as a dynamic mixture of a dominant strain in combination with minor substrains. To overcome this obstacle, therapies that reduce or eliminate the template of conversion are efficacious, may reverse neuropathology, and do not result in the emergence of drug resistance. Recent advancements in preclinical diagnosis of prion infection may allow for a combinational approach that treats the prion form and the precursor protein to effectively treat prion diseases.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-prion therapy; Prion disease; Prion strains

Mesh:

Substances:

Year:  2020        PMID: 32958242      PMCID: PMC8939712          DOI: 10.1016/bs.pmbts.2020.07.001

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  280 in total

1.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.

Authors:  D Peretz; R A Williamson; K Kaneko; J Vergara; E Leclerc; G Schmitt-Ulms; I R Mehlhorn; G Legname; M R Wormald; P M Rudd; R A Dwek; D R Burton; S B Prusiner
Journal:  Nature       Date:  2001-08-16       Impact factor: 49.962

2.  Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.

Authors:  Chan-Lan Kim; Ayako Karino; Naotaka Ishiguro; Morikazu Shinagawa; Motoyoshi Sato; Motohiro Horiuchi
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

3.  Interactions of recombinant prions with compounds of therapeutical significance.

Authors:  Dessislava Georgieva; Daniel Schwark; Martin von Bergen; Lars Redecke; Nicolay Genov; Christian Betzel
Journal:  Biochem Biophys Res Commun       Date:  2006-03-30       Impact factor: 3.575

4.  Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.

Authors:  Cécile Féraudet; Nathalie Morel; Stéphanie Simon; Hervé Volland; Yveline Frobert; Christophe Créminon; Didier Vilette; Sylvain Lehmann; Jacques Grassi
Journal:  J Biol Chem       Date:  2004-12-23       Impact factor: 5.157

5.  Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.

Authors:  P Parchi; R Castellani; S Capellari; B Ghetti; K Young; S G Chen; M Farlow; D W Dickson; A A Sima; J Q Trojanowski; R B Petersen; P Gambetti
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

6.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Authors:  Sarah K Kaufman; David W Sanders; Talitha L Thomas; Allison J Ruchinskas; Jaime Vaquer-Alicea; Apurwa M Sharma; Timothy M Miller; Marc I Diamond
Journal:  Neuron       Date:  2016-10-27       Impact factor: 17.173

7.  Therapeutic effect of peripheral administration of an anti-prion protein antibody on mice infected with prions.

Authors:  Natsuo Ohsawa; Chang-Hyun Song; Akio Suzuki; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  Microbiol Immunol       Date:  2013-04       Impact factor: 1.955

8.  Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.

Authors:  Jing L Guo; Sneha Narasimhan; Lakshmi Changolkar; Zhuohao He; Anna Stieber; Bin Zhang; Ronald J Gathagan; Michiyo Iba; Jennifer D McBride; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2016-10-17       Impact factor: 14.307

9.  Acquisition of drug resistance and dependence by prions.

Authors:  Anja M Oelschlegel; Charles Weissmann
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

10.  Amphotericin B induces glial cell line-derived neurotrophic factor in the rat brain.

Authors:  Akiko Motoyoshi-Yamashiro; Katsura Takano; Kenji Kawabe; Takeshi Izawa; Hidemitsu Nakajima; Mitsuaki Moriyama; Yoichi Nakamura
Journal:  J Vet Med Sci       Date:  2014-10-03       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.